Payment overview · 2025
General Payments
$284.40
14 reported records · 6 companies
Healthcare provider profile · identity verified
Wadih Kabbara, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BECKLEY, WV · NPI 1417977273
Verified facts
What the public records show
CMS Open Payments records show Wadih Kabbara, MD received $284.40 in general payments during 2025 across 14 reported records.
AstraZeneca Pharmaceuticals LP accounted for 58.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 159 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $167.25 | 58.8% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $32.21 | 11.3% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $25.21 | 8.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $20.81 | 7.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.51 | 6.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $19.41 | 6.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $284.40 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $110.80 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $41.87 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $25.21 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $20.81 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $19.51 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.51 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $19.41 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $19.41 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.63 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 159 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 69 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
53 | 15 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
54 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
58 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
25 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
69 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
112 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
159 | 43 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 777 | 215 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 662 | 69 |
| Amlodipine Besylate | Amlodipine Besylate | 644 | 144 |
| Pantoprazole Sodium | Pantoprazole Sodium | 506 | 122 |
| Levothyroxine Sodium | Levothyroxine Sodium | 456 | 97 |
| Metoprolol Succinate | Metoprolol Succinate | 377 | 86 |
| Gabapentin | Gabapentin | 369 | 54 |
| Montelukast Sodium | Montelukast Sodium | 349 | 80 |
| Omeprazole | Omeprazole | 338 | 83 |
| Lisinopril | Lisinopril | 325 | 75 |
| Tramadol Hcl | Tramadol Hcl | 285 | 42 |
| Trazodone Hcl | Trazodone Hcl | 267 | 52 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 246 | 59 |
| Clopidogrel | Clopidogrel Bisulfate | 240 | 75 |
| Furosemide | Furosemide | 239 | 69 |
| Tamsulosin Hcl | Tamsulosin Hcl | 231 | 44 |
| Hydralazine Hcl | Hydralazine Hcl | 229 | 60 |
| Celecoxib | Celecoxib | 222 | 58 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 218 | 58 |
| Fluticasone Propionate | Fluticasone Propionate | 208 | 69 |
| Potassium Chloride | Potassium Chloride | 201 | 54 |
| Losartan Potassium | Losartan Potassium | 197 | 48 |
| Metformin Hcl | Metformin Hcl | 197 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 187 | 57 |
| Citalopram Hbr | Citalopram Hydrobromide | 178 | 37 |
| Buspirone Hcl | Buspirone Hcl | 174 | 41 |
| Famotidine | Famotidine | 163 | 46 |
| Eliquis | Apixaban | 159 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 157 | 35 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 155 | 37 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 141 | 28 |
| Ropinirole Hcl | Ropinirole Hcl | 134 | 26 |
| Sucralfate | Sucralfate | 130 | 33 |
| Doxycycline Hyclate | Doxycycline Hyclate | 121 | 99 |
| Clonidine Hcl | Clonidine Hcl | 117 | 25 |
| Donepezil Hcl | Donepezil Hcl | 116 | 18 |
| Pregabalin | Pregabalin | 114 | 20 |
| Ozempic | Semaglutide | 112 | 21 |
| Methylprednisolone | Methylprednisolone | 108 | 80 |
| Carvedilol | Carvedilol | 98 | 22 |
| Azithromycin | Azithromycin | 96 | 67 |
| Escitalopram Oxalate | Escitalopram Oxalate | 92 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 92 | 21 |
| Amitriptyline Hcl | Amitriptyline Hcl | 91 | 26 |
| Januvia | Sitagliptin Phosphate | 87 | 21 |
| Valsartan | Valsartan | 87 | 15 |
| Alprazolam | Alprazolam | 81 | suppressed |
| Levofloxacin | Levofloxacin | 79 | 72 |
| Duloxetine Hcl | Duloxetine Hcl | 78 | 21 |
| Baclofen | Baclofen | 76 | 32 |
| Finasteride | Finasteride | 73 | 13 |
| Lorazepam | Lorazepam | 69 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 69 | 19 |
| Xarelto | Rivaroxaban | 67 | 12 |
| Sertraline Hcl | Sertraline Hcl | 64 | 11 |
| Spironolactone | Spironolactone | 64 | 17 |
| Allopurinol | Allopurinol | 63 | 16 |
| Brilinta | Ticagrelor | 58 | 19 |
| Ezetimibe | Ezetimibe | 57 | 20 |
| Propranolol Hcl | Propranolol Hcl | 57 | 20 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 57 | 41 |
| Levetiracetam | Levetiracetam | 55 | 16 |
| Ventolin Hfa | Albuterol Sulfate | 55 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 54 | 15 |
| Synthroid | Levothyroxine Sodium | 54 | 12 |
| Linzess | Linaclotide | 53 | 15 |
| Topiramate | Topiramate | 53 | 13 |
| Trulicity | Dulaglutide | 52 | suppressed |
| Prednisone | Prednisone | 51 | 35 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 50 | 17 |
| Nitroglycerin | Nitroglycerin | 50 | 19 |
| Cefdinir | Cefdinir | 49 | 40 |
| Alendronate Sodium | Alendronate Sodium | 48 | 14 |
| Diazepam | Diazepam | 48 | suppressed |
| Meloxicam | Meloxicam | 48 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 48 | suppressed |
| Ranolazine Er | Ranolazine | 46 | 15 |
| Tradjenta | Linagliptin | 46 | suppressed |
| Entresto | Sacubitril/Valsartan | 44 | 20 |
| Cilostazol | Cilostazol | 42 | suppressed |
| Glipizide | Glipizide | 42 | suppressed |
| Jardiance | Empagliflozin | 42 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 41 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 41 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 40 | 11 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 40 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 38 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 36 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 36 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 35 | suppressed |
| Nifedipine Er | Nifedipine | 35 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 35 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 34 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 32 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 32 | suppressed |
| Pentoxifylline | Pentoxifylline | 32 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 31 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 23 |
| Diltiazem Hcl | Diltiazem Hcl | 28 | suppressed |
| Simvastatin | Simvastatin | 28 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 28 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Lactulose | Lactulose | 26 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 26 | suppressed |
| Nystatin | Nystatin | 26 | 17 |
| Atenolol | Atenolol | 25 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 25 | suppressed |
| Metronidazole | Metronidazole | 25 | 24 |
| Prasugrel Hcl | Prasugrel Hcl | 25 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 25 | 14 |
| Valacyclovir | Valacyclovir Hcl | 25 | suppressed |
| Aripiprazole | Aripiprazole | 24 | suppressed |
| Colchicine | Colchicine | 24 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 24 | suppressed |
| Novolog Flexpen | Insulin Aspart | 23 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 22 | 15 |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Glimepiride | Glimepiride | 22 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | 14 |
| Candesartan Cilexetil | Candesartan Cilexetil | 19 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 17 | 16 |
| Clonazepam | Clonazepam | 17 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | 14 |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 17 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 14 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 12 | suppressed |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Euthyrox | Levothyroxine Sodium | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Benicar Hct | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Nabumetone | Nabumetone | 11 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $284.40 · 14 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, ELIQUIS, FARXIGA, JARDIANCE, NURTEC ODT, QULIPTA, TRELEGY ELLIPTA, UBRELVY, Wegovy | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error